NASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis $9.85 -0.96 (-8.88%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$10.22 +0.37 (+3.76%) As of 05/23/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Syndax Pharmaceuticals Stock (NASDAQ:SNDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Syndax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$9.83▼$11.0450-Day Range$8.95▼$14.1552-Week Range$8.58▼$25.07Volume3.90 million shsAverage Volume1.77 million shsMarket Capitalization$847.56 millionP/E RatioN/ADividend YieldN/APrice Target$35.91Consensus RatingModerate Buy Company OverviewSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More… Syndax Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreSNDX MarketRank™: Syndax Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 227th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Syndax Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($3.72) to ($4.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Syndax Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.17% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently increased by 2.31%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.12 Percentage of Shares Shorted25.17% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently increased by 2.31%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment1.36 News SentimentSyndax Pharmaceuticals has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Syndax Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.Read more about Syndax Pharmaceuticals' insider trading history. Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SNDX Stock News HeadlinesSyndax Pharmaceuticals Inc.May 21 at 1:56 AM | wsj.comSyndax Pharmaceuticals Presents Promising Clinical Data for Revuforj® and Niktimvo™ at the EHA Annual Congress 2025May 16, 2025 | nasdaq.comTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?May 24, 2025 | Augusta Precious Metals (Ad)Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)May 14, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical OfficerMay 13, 2025 | finanznachrichten.deSyndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical OfficerMay 12, 2025 | globenewswire.comSyndax Announces Participation in May Investor ConferencesMay 8, 2025 | globenewswire.comSyndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal BloodMay 7, 2025 | globenewswire.comSee More Headlines SNDX Stock Analysis - Frequently Asked Questions How have SNDX shares performed this year? Syndax Pharmaceuticals' stock was trading at $13.22 at the beginning of the year. Since then, SNDX shares have decreased by 25.5% and is now trading at $9.85. View the best growth stocks for 2025 here. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its quarterly earnings data on Monday, May, 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.06. Syndax Pharmaceuticals's quarterly revenue was up 1900.0% on a year-over-year basis. Read the conference call transcript. When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Top institutional shareholders of Syndax Pharmaceuticals include Vanguard Group Inc. (5.66%), Goldman Sachs Group Inc. (4.56%), Assenagon Asset Management S.A. (2.37%) and Algert Global LLC (1.03%). Insiders that own company stock include Michael A Metzger, Keith A Goldan, Neil Gallagher, Dennis Podlesak, William Meury, Pierre Legault, Keith Katkin, Briggs Morrison and Peter Ordentlich. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW). Company Calendar Last Earnings5/05/2025Today5/23/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNDX CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$35.91 High Stock Price Target$51.00 Low Stock Price Target$17.00 Potential Upside/Downside+264.6%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,360,000.00 Net MarginsN/A Pretax Margin-1,856.64% Return on Equity-64.34% Return on Assets-57.72% Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.99 Sales & Book Value Annual Sales$43.72 million Price / Sales19.39 Cash FlowN/A Price / Cash FlowN/A Book Value$6.53 per share Price / Book1.51Miscellaneous Outstanding Shares86,047,000Free Float81,858,000Market Cap$847.56 million OptionableOptionable Beta0.82 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:SNDX) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.